Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Mannkind Corp 1 CASPER STREET DANBURY CT 06810 USA

www.mannkindcorp.com Employees: 407 P: 818-661-5000

Sector:

Medical

Description:

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.

Key Statistics

Overview:

Market Capitalization, $K 1,698,097
Enterprise Value, $K 1,745,637
Shares Outstanding, K 307,070
Float, K 298,779
% Float 97.30%
Short Interest, K 26,239
Short Float 8.55%
Days to Cover 5.63
Short Volume Ratio 0.47
% of Insider Shareholders 2.70%
% of Institutional Shareholders 49.55%

Financials:

Annual Sales, $ 285,500 K
Annual Net Income, $ 27,590 K
Last Quarter Sales, $ 82,130 K
Last Quarter Net Income, $ 7,990 K
EBIT, $ 72,980 K
EBITDA, $ 83,670 K

Growth:

1-Year Return -2.65%
3-Year Return 2.22%
5-Year Return -3.15%
5-Year Revenue Growth 352.89%
5-Year Earnings Growth 137.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.03 on 11/05/25
Next Earnings Date 02/26/26 [BMO]
Earnings Per Share ttm 0.10
EPS Growth vs. Prev Qtr 33.33%
EPS Growth vs. Prev Year -25.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 03/03/17

MNKD Ratios

Ratio
Price/Earnings ttm 54.40
Price/Earnings forward 62.96
Price/Earnings to Growth N/A
Return-on-Equity % -49.33%
Return-on-Assets % 6.84%
Profit Margin % 9.66%
Debt/Equity -4.79
Price/Sales 5.42
Price/Cash Flow 39.92
Price/Book N/A
Book Value/Share -0.15
Interest Coverage -1.80
60-Month Beta 0.84
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar